Aaysha Saifi,
Sadaf Saifi,
- Research Scholar, Department of Microbiology, Monad University Pilakhwa Ghaziabad, Uttar Pradesh, India
- Student, Department of Microbiology, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India
Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_127758’);});Edit Abstract & Keyword
Squamous intraepithelial lesions (SILs), which are a kind of cancer, and HUMAN papillomavirus (HPV) viral load have frequently been investigating as a risk factors in finding that were in dispute. These studies made use of several HPV viral quantitation assay [including the commercially available hybrid capture 2 (HC2) assay], which vary in their capacity to take into account variations in cervical cell collection, linear dynamic range of viral load quantitation, and identified type- specific compared to cumulative viral load measures. Real-time PCR assays were used to quantify the viral loads of HPV 16 and HPV 18 in order to see if they differed from HC2 quantitation ( which does not account for cellularity or multiple infection) in terms of the relation ship between viral load and prevalent the SIL and malignancies. In general population, such as the real time PCR measurement of HPV-16, or viral load rose linearly according to the increasing grade of SIL, but the measurement of HPV-18 used equivalent method increased via low grade SIL (LSIL), with high grade SIL experiencing a higher viral load of HPV-18 and malignancies occurring at a rate equivalent to that of cytologically healthy woman. Utilizing the clinical cut point of 1.0 pg/ml, HC2 viral load distinguished between woman with any level of cytological abnormalities ( i.e., normal verses >LSIL) and woman who had cytologically normal tissue, but did the alter as the severity of the lesion rose. HC2 did not appear to plateau at large copy number, and there was no indication of considerable variation in the overall cellularity of the specimens. HC2 estimation of the total viral load, however, overstated the total viral load caused by each individuals kind of coinfection.
Keywords: Human papillomavirus, Real-time PCR, HPV 16, HC2, SIL
Aaysha Saifi, Sadaf Saifi. Comparison Of A Human Papillomavirus Test With The Hybrid Capture 2 And A Real Time PCR Method For 18 High Risk And Low Risk Human Papillomavirus Infection In Woman. Research & Reviews: A Journal of Microbiology & Virology. 2024; ():-.
Aaysha Saifi, Sadaf Saifi. Comparison Of A Human Papillomavirus Test With The Hybrid Capture 2 And A Real Time PCR Method For 18 High Risk And Low Risk Human Papillomavirus Infection In Woman. Research & Reviews: A Journal of Microbiology & Virology. 2024; ():-. Available from: https://journals.stmjournals.com/rrjomv/article=2024/view=0
References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_127758’);});Edit
- Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiology Biomarkers & Prevention. 2003 Jun 1;12(6):477-84.
- Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E, Gyllensten U. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. Journal of clinical virology. 2009 Jun 1;45(2):85-9.
- Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, Branovskaja M. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. Journal of Clinical Microbiology. 2004 Jun;42(6):2470-5.
- Hooper JE, Hebert JF, Schilling A, Gross ND, Schindler JS, Lagowski JP, Kulesz-Martin M, Corless CL, Morgan TK. Hybrid capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers. Applied Immunohistochemistry & Molecular Morphology. 2015 Apr 1;23(4):266-72.
- Park Y, Lee E, Choi J, Jeong S, Kim HS. Comparison of the Abbott RealTi me High-Risk human papillomavirus (HPV), Roche cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. Journal of clinical microbiology. 2012 Jul;50(7):2359-65.
- Lee JH, Lee NW, Hong SW, Nam YS, Choi JW, Kim YS. Establishment of an efficient multiplex real‐time PCR assay for human papillomavirus genotyping in cervical cytology specimens: comparison with hybrid capture II. Cytopathology. 2011 Aug;22(4):261-8.
- Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. Journal of Clinical Virology. 2013 Sep 1;58(1):161-7.
- Venturoli S, Leo E, Nocera M, Barbieri D, Cricca M, Costa S, Santini D, Zerbini M. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting. Journal of clinical virology. 2012 Feb 1;53(2):121-4.
- Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, ALTS Group. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. American journal of clinical pathology. 2005 Nov 1;124(5):722-32.
- Hesselink AT, van den Brule AJ, Brink AA, Berkhof J, Van Kemenade FJ, Verheijen RH, Snijders PJ. Comparison of hybrid capture 2 with in situ hybridization for the detection of high‐risk human papillomavirus in liquid‐based cervical samples. Cancer Cytopathology: Interdisciplinary International Journal of the American Cancer Society. 2004 Feb 25;102(1):11-8.
Research & Reviews: A Journal of Microbiology & Virology
| Volume | |
| Received | 24/10/2024 |
| Accepted | 13/12/2024 |
| Published | 14/12/2024 |